Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
27
Aug |
Clarifying Conflict Of Interest Disclosures In Clinical TrialsCategory: Clinical Trials / Drug Trials | Leave a Comment |
When enrolling patients in a clinical trial, researchers should disclose relevant financial relationships that might affect a patient’s decision about participation, such as owning stock in the company that funds the study, or having a patent on the device being tested. It’s a process many believe builds trust and fulfills a patient’s right to know about financial conflicts of interest.
|
24
Apr |
Almac And PHT Announce Formal Alliance To Improve Clinical Trial Data QualityCategory: Clinical Trials / Drug Trials | Leave a Comment |
Almac Clinical Technologies and PHT Corporation announced a formal alliance to improve clinical trial productivity through a variety of education initiatives and data integration efforts that will reduce clinical trial site burdens while improving study data collection and reporting.
|
17
Apr |
Powerful New IPhone App For Health Care Industry Allows Search Of All Registered Clinical TrialsCategory: Clinical Trials / Drug Trials | Leave a Comment |
Before today, searching for one of more than 71,500 clinical trials in the National Library of Medicine and National Institutes of Health database required a chair, computer, internet connection, and a session on the government’s clinical trials website. A powerful new iPhone application called ‘Clinical Trials,’ however, gives physicians, health care practitioners and other professionals in the medical industry a way to search for clinical trials from anywhere and at any time.
|
7
Nov |
Bilcare GCS Expands Pre-Clinical And Early-Stage Development CapabilitiesCategory: Clinical Trials / Drug Trials | Leave a Comment |
In its endeavor to accelerate the drug development process cycle and help clients increase their speed to market, Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial supplies and services, has enhanced its ability to develop functionally viable and innovative formulation dosage forms for pre-clinical and early-phase drugs.
|
23
Oct |
China Clinical Development Summit Highlights New Opportunities For Western Pharma, Biotech And CROs At Major Industry EventCategory: Clinical Trials / Drug Trials | Leave a Comment |
Hundreds of clinical development executives from the pharmaceutical, biotech, and CRO sectors will gather on November 9-11 in Shanghai to attend the industry’s first major international conference covering China’s booming clinical development industry. The preliminary attendee list has been posted to encourage pre-conference networking on the event website at http://www.chinatrialsevent.com.